Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflect continued ...
Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced ...
In the days when that healthcare segment was relatively limited, Teva ruled its niche. But success attracts competition, and ...
April 29 (Reuters) - Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped ...
Blackstone committed $400 million to fund development of Teva's promising autoimmune disease drug duvakitug. This deal ...
5d
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...
Teva (TEVA) stock jumps as the company exceeds forecasts with Q1 2026 financials. However, it cut its 2026 earnings outlook ...
Teva Pharmaceuticals' first-quarter net income rose on higher revenue and the Israeli maker of generic and branded drugs agreed to buy a closely held drug developer focused on a Tourette syndrome ...
Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results